Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

Masato Tashiro, Koichi Izumikawa*, Asuka Minematsu, Katsuji Hirano, Naoki Iwanaga, Shotaro Ide, Tomo Mihara, Naoki Hosogaya, Takahiro Takazono, Yoshitomo Morinaga, Shigeki Nakamura, Shintaro Kurihara, Yoshifumi Imamura, Taiga Miyazaki, Tomoya Nishino, Misuzu Tsukamoto, Hiroshi Kakeya, Yoshihiro Yamamoto, Katsunori Yanagihara, Akira YasuokaTakayoshi Tashiro, Shigeru Kohno

*この論文の責任著者

研究成果: ジャーナルへの寄稿学術論文査読

76 被引用数 (Scopus)

抄録

We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively.

本文言語英語
ページ(範囲)584-587
ページ数4
ジャーナルAntimicrobial Agents and Chemotherapy
56
1
DOI
出版ステータス出版済み - 2012/01

ASJC Scopus 主題領域

  • 薬理学
  • 薬理学(医学)
  • 感染症

フィンガープリント

「Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル